drugset / Trial / NCT02246465

A Study to Evaluate the Effectiveness and Safety of RXI 109 on the Outcome of Revised Hypertrophic Scars

NCT02246465 ↗

Phase 2 Unknown 40 enrolled RXi Pharmaceuticals, Corp.
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the effectiveness of RXI-109 in reducing the recurrence of hypertrophic scar formation following elective revision of a pre-existing hypertrophic scar.

Timeline

Start
2014-07
Primary completion
2017-12
Completion
2018-03

Drugs

EvaluationDrugModalityDoseRoute
Subject RXI-109 Unknown — —